

References.

- [1] Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. *JAMA Netw Open*. 2020 Aug 3;3(8):e2014674. doi: 10.1001/jamanetworkopen.2020.14674.
- [2] Zelefsky MJ, Pei X, Chou JF, *et al*. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. *Eur Urol*. 2011 Dec;60(6):1133-9. doi: 10.1016/j.eururo.2011.08.029.
- [3] Kuban DA, Tucker SL, Dong L, *et al*. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2008 Jan 1;70(1):67-74. doi: 10.1016/j.ijrobp.2007.06.054.
- [4] Peeters ST, Heemsbergen WD, Koper PC, *et al*. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. *J Clin Oncol*. 2006 May 1;24(13):1990-6. doi: 10.1200/JCO.2005.05.2530.
- [5] Dearnaley DP, Sydes MR, Graham JD, *et al*. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. *Lancet Oncol*. 2007 Jun;8(6):475-87. doi: 10.1016/S1470-2045(07)70143-2.
- [6] Morris WJ, Tyldesley S, Rodda S, *et al*. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. *Int J Radiat Oncol Biol Phys*. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026.

- [7] Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. *Radiother Oncol*. 2012 May;103(2):217-22. doi: 10.1016/j.radonc.2012.01.007.
- [8] Pettersson A, Alm D, Garmo H, *et al*. Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study. *JNCI Cancer Spectr*. 2020 Feb 14;4(2):pkaa006. doi: 10.1093/jncics/pkaa006.
- [9] Fischer-Valuck BW, Rao YJ, Brenneman RJ, *et al*. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. *Brachytherapy*. 2020 Sep-Oct;19(5):557-566. doi: 10.1016/j.brachy.2020.05.007.
- [10] Glaser SM, Dohopolski MJ, Balasubramani GK, Benoit RM, Smith RP, Beriwal S. Brachytherapy boost for prostate cancer: Trends in care and survival outcomes. *Brachytherapy*. 2017 Mar-Apr;16(2):330-341. doi: 10.1016/j.brachy.2016.12.015.
- [11] Ennis RD, Hu L, Ryemon SN, Lin J, Mazumdar M. Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer. *J Clin Oncol*. 2018 Apr 20;36(12):1192-1198. doi: 10.1200/JCO.2017.75.9134.
- [12] Kishan AU, Cook RR, Ciezki JP, *et al*. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. *JAMA*. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.
- [13] Zheng J, Bachand F, Halperin R, Kim D, Petrik D, Crook J. PRSOR06 Presentation Time: 12:25 PM: After ASCENDE-RT: Outcomes of Androgen Deprivation, External Beam Radiation and LDR

- Brachytherapy Boost for High-Tier Intermediate and High Risk Prostate Cancer. *Brachytherapy* 2021;20:S45. doi: 10.1016/J.BRACHY.2021.06.070.
- [14] Hsu IC, Rodgers JP, Shinohara K, *et al.* Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. *Int J Radiat Oncol Biol Phys*. 2021 Jul 1;110(3):700-707. doi: 10.1016/j.ijrobp.2020.11.008.
- [15] Prada PJ, González H, Fernández J, Jiménez I, Iglesias A, Romo I. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience. *BJU Int*. 2012 Jun;109(12):1787-93. doi: 10.1111/j.1464-410X.2011.10632.x.
- [16] Kent AR, Matheson B, Millar JL. Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone. *Brachytherapy*. 2019 May-Jun;18(3):313-321. doi: 10.1016/j.brachy.2019.01.013.
- [17] Lin YW, Lin LC, Lin KL. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer. *Front Oncol* 2014;4. doi: 10.3389/fonc.2014.00278.
- [18] Kim HJ, Phak JH, Kim WC. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer. *Asia Pac J Clin Oncol* 2017;13:e342–e347. doi: 10.1111/ajco.12455.
- [19] Katz A, Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. *Radiat Oncol* 2014;9. doi: 10.1186/1748-717X-9-1.
- [20] Mercado C, Kress MA, Cyr RA, *et al.* Intensity-Modulated Radiation Therapy with Stereotactic

Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. *Front Oncol* 2016;6. doi: 10.3389/FONC.2016.00114.

- [21] Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. *Radiat Oncol* 2016;11. doi: 10.1186/S13014-016-0585-Y.
- [22] Eade T, Hruby G, Booth J, *et al.* Results of a Prospective Dose Escalation Study of Linear Accelerator-Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer. *Adv Radiat Oncol*. 2019 Apr 11;4(4):623-630. doi: 10.1016/j.adro.2019.03.015.
- [23] Pryor D, Sidhom M, Arumugam S, *et al.* Phase 2 Multicenter Study of Gantry-Based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS). *Front Oncol*. 2019 Apr 2;9:217. doi: 10.3389/fonc.2019.00217.
- [24] Musunuru HB, D'Alimonte L, Davidson M, *et al.* Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. *Int J Radiat Oncol Biol Phys* 2018;102:1438–1447. doi: 10.1016/J.IJROBP.2018.07.2005.
- [25] McClelland S 3rd, Sandler KA, Degrin C, Chen Y, Mitin T. Dramatically Polarized Opinion on the Role of Brachytherapy Boost in Management of High-risk Prostate Cancer: A Survey of North American Genitourinary Expert Radiation Oncologists. *Clin Genitourin Cancer*. 2018 Jun;16(3):e543-e545. doi: 10.1016/j.clgc.2018.01.001.
- [26] Chen WC, Li Y, Lazar A, *et al.* Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized

Prostate Cancer: A Single-Institution Propensity Score Matched Analysis. *Int J Radiat Oncol Biol Phys* 2021;110:429–437. doi: 10.1016/J.IJROBP.2020.12.034.

- [27] Agarwal M, Chhabra AM, Amin N, Braccioforte MH, Molitoris JK, Moran BJ. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer. *Brachytherapy*. 2018 Nov-Dec;17(6):882-887. doi: 10.1016/j.brachy.2018.07.001.